Skip to content
AnthologyRX

Is PT-141 safe?

Safety starts with the specific treatment, your health history and a source you can verify. Here is what to understand before considering PT-141.

View PT-141 plans and pricing

What does the safety evidence cover?

PT-141 is another name for bremelanotide. The largest published trials studied an injection in premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. They did not test AnthologyRX’s planned compounded nasal preparation. Read the phase 3 research.

That distinction matters when someone calls PT-141 “safe.” Ask which product, which patients and which evidence they mean. Your own prescription deserves a more specific answer than a reassuring adjective.

Side effects and screening

The Vyleesi prescribing information identifies these issues:

  • Nausea: reported by 40% of treated patients versus 1.3% on placebo in the phase 3 trials. Flushing, injection-site reactions, headache and vomiting also occurred.
  • Cardiovascular effects: temporary blood-pressure increases and heart-rate reductions. Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease.
  • Skin darkening: pigmentation changes may persist.
  • Interactions: slowed stomach emptying can affect oral medicines. Avoid Vyleesi with oral naltrexone used for alcohol or opioid dependence.
  • Pregnancy: the label advises effective contraception and stopping Vyleesi if pregnancy is suspected.

Bring your complete medication list, recent blood-pressure information and relevant medical history to the Assessment. Include supplements, recreational substances, pregnancy plans and any previous reaction to treatment. Use the clinician's and dispensing pharmacy's instructions for your specific prescription.

Is compounded PT-141 FDA-approved?

No. Our planned PT-141 offering is a compounded nasal spray, not Vyleesi, and is currently awaiting availability. Compounded drugs do not receive FDA premarket review for safety, effectiveness or quality. FDA explains the distinction.

Reviewing the molecule's clinical data is one part of evaluating care. Verifying the prescribing clinician, dispensing pharmacy and exact preparation is another. Our guide to evaluating a peptide provider gives you questions and official lookup tools for both.

What about safety for men?

Vyleesi is not indicated for men. A clinician considering compounded PT-141 for a man must assess the evidence and individual risks separately. The women's approval trials cannot settle that question. See what the research in men actually studied.

What happens if I am not approved?

Your clinician explains the decision and, where useful, recommends a next step. If you choose not to proceed with treatment, you will not be charged, even after your clinical consultation. If treatment is not approved, you will not be charged. Read the refund policy.

Sources

  1. Vyleesi prescribing information

    DailyMed. Indication, contraindications, adverse reactions and interactions.

  2. Kingsberg et al. Two randomized phase 3 bremelanotide trials

    Obstetrics & Gynecology, 2019. DOI: 10.1097/AOG.0000000000003500.

  3. FDA: Compounding questions and answers

    The distinction between compounded medications and FDA-approved drug products.

AnthologyRX
Find your treatment
Browse all treatments